Publications by authors named "Allison Imahiyerobo"
Patients with congenital thrombocytopenia have an increased risk of developing myeloid neoplasms. In these cases, the morphologic distinction between disease at baseline and at progression is challenging. This report analyzes clinicopathologic features of congenital thrombocytopenia with long-term follow-up at one referral center.
View Article and Find Full Text PDFPlatelet counts (PC) estimate bleeding risk in Immune Thrombocytopenia (ITP). We investigated whether measures of thromboelastometry and absolute immature platelet fraction (A-IPF) would correlate better with acute bleeding score (ABS) than PC or mean platelet volume (MPV). Simultaneous determination of ABS, complete blood count and thromboelastometry was performed in 141 ITP patients; 112 underwent A-IPF testing.
View Article and Find Full Text PDFArticle Synopsis
- Studies indicate that combining several doses of dexamethasone with rituximab yields significantly better results compared to using either treatment alone.
- A trial involving 67 patients showed that 64% had complete responses after treatment and that factors like less than 24 months of illness duration and being female linked to better long-term outcomes, despite some patients experiencing mild to moderate side effects.
Article Synopsis
- - Thrombopoietin-receptor agonists increase platelet counts but are linked to the development of myelofibrosis in patients with immune thrombocytopenia, with significant changes observed in bone marrow biopsies over time.
- - The study assessed 66 patients, revealing a decrease in the proportion of biopsies showing no fibrosis from 67% before treatment to only 22% after, with higher fibrosis grades increasingly observed in those treated for over 2 years.
- - The findings suggest regular monitoring via bone marrow biopsies is necessary to identify and potentially discontinue treatment if severe myelofibrosis grades develop, which could help prevent further complications.